Frontlight ResearchEarly access
CompletedPhase 4
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
Key facts
- Who runs it
- CSL Behring
- Where
- Baltimore, Centennial, Litchfield Park, Oklahoma City, Pittsburgh, Plymouth, Scottsdale, and St Louis, United StatesSee the 8 sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 8 people enrolled
- Started
- 15 Jul 2025
- Ended
- 30 Jun 2026
- Type of study
- Interventional
- Treatments tested
- IgPro
- Record updated
- 16 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Participants must be aged >=18 years
- Participants must have a confirmed and documented diagnosis of PID, must be IG treatment-naïve and have an IgG level less than or equal to (<=) 400 milligrams per deciliter(mg/dL) at Screening
Who cannot take part
- Participants who are receiving the following medications:
- Systemic corticosteroids (prednisone or equivalent; average daily dose of greater than [>] 15 mg) from 4 weeks before Screening
- Any dose of systemic immunosuppressants within 9 months or 5 times the half-life (t½) plus 6 months before Screening, whichever is longer
- Any dose of biologic therapies with influence on the immune system (eg, tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors), including investigational agents, within 12 months or 5 times the t½ plus 6 months before Screening, whichever is longer
- Participants who are currently receiving anti-coagulation therapy
- Participants with a documented history or a current diagnosis of a thromboembolic event(s) (eg, deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident, transient ischemic attack) or coagulopathy within 12 months before Screening
- Participants with hypoalbuminemia, protein-losing enteropathies, and kidney diseases with proteinuria
- Participants with severe dehydration and known blood disorders affecting viscosity
- Participants with new onset or worsening or severe cardiac, pulmonary, kidney disease, and liver disease
- Participants with malignancies of lymphoid cells such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and immunodeficiency with thymoma
- Participants with aspartate aminotransferase and alanine aminotransferase concentration > 3 times the upper limit of normal (ULN; central laboratory) at Screening
- Participants with creatinine concentration > 1.5 times the ULN (central laboratory) at Screening
- Participants with hyperprolinemia
Where in United States
- Johns Hopkins Bayview Medical CenterBaltimore, United States
- Immunoe Health CentersCentennial, United States
- Research Solutions of AZLitchfield Park, United States
- Allergy Asthma and Clinical Research CenterOklahoma City, United States
- Allergy & Clinical ImmunologyPittsburgh, United States
- Midwest ImmunologyPlymouth, United States
- Medical Research of ArizonaScottsdale, United States
- Washington UniversitySt Louis, United States
About the trial
What the trial wants to find out
This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK, safety, and tolerability of IgPro20. The primary objective of this study is to characterize the PK of IgPro20 and to assess the safety and tolerability of IgPro20 in IG treatment-naïve participants with PID who are aged greater than or equal to (>=) 18 years.
The group in the trial
- IgPro20Treatment being tested
All participants will receive a loading dose of IgPro20 daily from Day 1 to 5 in Week 1, followed by weekly administration of the maintenance dose of IgPro20 from Day 8 (Week 2) to Day 78 (Week 12).
Treatment: IgPro
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-naïve Subjects With Primary Immunodeficiency
- Record updated
- 16 July 2026